2017-04-18T00:00:00-05:00 2016-12-31 042088368 GRAY GRAY & GRAY LLP 150 ROYALL STREET SUITE 102 CANTON MA 02021 990 2016-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST NO 200 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2017-04-10 1 RICHARD D TARDIFF P00154902 7814070300 2017-04-06 50.234.152.46 2017-04-10 10:37:12 ED P FE63424659D3925972608316E315838AD83887F2 4CB60F71B332EFE142C1B35711A0205FB6B82728 2016 2021-01-29 14:40:06Z CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON STREET WELLESLEY HILLS MA 02493 20070730 0 X WWW.CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTRHOPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 8 7 17 42 0 0 11248214 16220862 0 0 -3438 -63796 3150 90 11247926 16157156 9717746 12429812 0 0 1026369 1298940 0 0 662484 2296583 2786682 13040698 16515434 -1792772 -358278 12424725 12463210 166819 563695 12257906 11899515 X FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 13455939 12429812 IN 2016, CURE ALZHEIMER'S FUND SUPPORTED 56 RESEARCH PROJECTS AT 32 LEADING RESEARCH INSTITUTIONS, FOR A FUNDING TOTAL OF MORE THAN $13 MILLION. THE MAJORITY OF PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT. 1676977 SUPPORT OF THE GRANTING PROCESS AND CREATING AWARENESS FOR THE NEED FOR MORE RESEARCH TOOK THE FORM OF MEETINGS OF THE RESEARCH CONSORTIUM TO REVIEW AND MODIFY CURE ALZHEIMER'S FUND'S RESEARCH AGENDA, SUPPORT OF THE SCIENTIFIC ADVISORY BOARD IN REVIEWING PROPOSALS AND MEETINGS, MAILINGS AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 11679 CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVES FUNDS FROM THE METROPOLITAN LIFE FOUNDATION, DISPENSES THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTS THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION. CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVES FUNDS FROM THE METROPOLITAN LIFE FOUNDATION, DISPENSES THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTS THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION 15144595 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 20 0 1 17 1 0 0 0 0 0 0 0 0 X 8 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812373800 34 WASHINGTON STREET STE 200 WELLESLEY HILLS MA 02481 JEFFREY MORBY CO-CHAIRMAN OF BOARD 20.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 HENRY MCCANCE CO-CHAIRMAN OF BOARD 5.00 X 0 0 0 PHYLLIS RAPPAPORT DIRECTOR 2.00 X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 TIMOTHY W ARMOUR PRESIDENT & CEO 40.00 X X 216933 0 0 MATTHEW SZULIK TREASURER 2.00 X X 0 0 0 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 MARGARET SMITH SECRETARY & SR VICE PRESIDENT 20.00 X 112942 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 40.00 X 161462 0 0 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 40.00 X 164984 0 8200 BARBARA CHAMBERS SENIOR ENGMT OFFICER, MARKETING & COMMUNICATIONS 40.00 X 161462 0 8600 817783 0 16800 5 0 1 0 GRYPHON CONSULTING LLC 21 DEAN ST BELMONT MA 02478 FINANACIAL AND MANAGEMENT CONSULTING 174667 O'NEIL & ASSOCIATES 31 NEW CHARDON ST BOSTON MA 02114 PUBLIC RELATIONS CONSULTING 130000 DAVID SHENK 216 ST JOHNS PLACE APT D BROOKLYN NY 11217 PROGRAM AND FUNDRAISING CONSULTING 120000 ALTSHULERSTAATS LLC 61 DEAN ROAD BROOKLINE MA 02445 MANAGEMENT CONSULTING 112500 4 16220862 3928416 16220862 611 611 3849167 3913574 -64407 -64407 -64407 OTHER INCOME 900099 90 90 90 16157156 -64317 0 611 12429812 12429812 834583 559583 102470 172530 331524 108122 82259 141143 32482 20940 4321 7221 25051 8830 6732 9489 75300 42921 12048 20331 31286 31286 141583 141583 367351 164000 176851 26500 48027 6701 41326 16598 15771 827 87285 49752 13966 23567 144141 106876 15729 21536 1700 1575 125 7034 7034 3950 3950 RESEARCH EXPENSES 1027182 1027182 PUBLIC RELATIONS 144070 144070 POSTAGE AND SHIPPING 127298 94244 5742 27312 PRINTING AND REPRODUCTI 107129 77757 2910 26462 532048 302230 85703 144115 16515434 15144595 708355 662484 2717780 2792710 7411840 6371310 2231768 3097825 45948 141354 66173 15264 8392 50909 8997 9102 12424725 12463210 91251 260603 75568 303092 166819 563695 X 10224238 8710240 2033668 3189275 12257906 11899515 12424725 12463210 -358278 -113 0 X 0 1 X 1 0 X 9103453 6388347 12640759 11248214 16220862 55601635 9103453 6388347 12640759 11248214 16220862 55601635 10743423 44858212 11166 -15933 11420 -3438 -63796 -60581 13447 10000 3150 90 26687 55567741 0.80730 0.75850 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 75376 0 0 75376 0 PART II-B, LINE 1: PART II-B, LINE 1(I), OTHER LOBBYING ACTIVITIES: A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 9939 1344 8595 56234 13920 42314 50909 ACCRUED EXPENSES 303092 303092 X 16170809 -113 13766 13653 16157156 0 16157156 16529200 13766 13766 16515434 0 16515434 PART X, LINE 2: CUREALZ WAS DETERMINED TO BE EXEMPT FROM FEDERAL INCOME TAX UNDER PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE OF 1986 (IRC) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION AS DEFINED IN SECTION 509(A)(3) OF THE IRC. ACCORDINGLY, NO PROVISIONS FOR FEDERAL OR STATE INCOME TAXES ARE REQUIRED. CUREALZ IS REQUIRED TO RECOGNIZE THE FINANCIAL STATEMENT IMPACT OF A TAX POSITION WHEN IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION. ANY INTEREST AND PENALTIES RECOGNIZED ASSOCIATED WITH A TAX POSITION WOULD BE CLASSIFIED AS CURRENT IN CUREALZ'S FINANCIAL STATEMENTS. CURRENTLY, THE TAX YEARS ENDED DECEMBER 31, 2013, 2014, AND 2015 ARE OPEN AND SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE AND THE MASSACHUSETTS DEPARTMENT OF REVENUE. HOWEVER, CUREALZ IS NOT CURRENTLY UNDER AUDIT NOR HAS CUREALZ BEEN CONTACTED BY ANY OF THESE JURISDICTIONS. BASED ON THE EVALUATION OF CUREALZ'S TAX POSITIONS, MANAGEMENT BELIEVES ALL POSITIONS TAKEN WOULD BE UPHELD UNDER AN EXAMINATION. THEREFORE, NO PROVISION FOR THE EFFECTS OF UNCERTAIN TAX POSITIONS HAS BEEN RECORDED FOR THE YEAR ENDED DECEMBER 31, 2016. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM GRANTS AWARDED 724908 0 0 0 0 0 0 724908 0 724908 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPUTIC MODULATION OF TREM2 ACTIVITY. 150000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) CIRCUITS: EPIGENETIC DETERMINANTS OF HUMAN COGNITIVE AGING 199600 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) CIRCUITS: UTILIZING FUNCTIONAL MAPS TO PRIORITIZE THERAPEUTIC TARGETS IN ALZHEIMER'S DISEASE 225308 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) NANOBODIES TO CROSS THE BLOOD-BRAIN BARRIER 150000 CHECK 0 0 0 0 0 0 PART I, LINE 2: THE CHAIR OF THE RESEARCH CONSORTIUM (RC) AND SUITABLE MEMBERS OF THE RC AND SCIENTIFIC ADVISORY BOARD (SAB) REVIEW EACH PROPOSAL FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S. THE BOARD OF DIRECTORS OF CURE ALZHEIMER'S FUND PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY MEMBER OF THE RC, SAB OR EXECUTIVE COMMITTEE WILL BE RETURNED TO THE RESEARCHER FOR CLARIFICATION. SUCH QUESTIONS OR CONCERNS MAY RESULT IN MODIFICATION AND RESUBMISSION, OR, IN EXTREME CASES, REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTION, OR REJECTION. THERE IS NO "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION WHEN RESEARCHERS ARE NOTIFIED THAT A PROPOSAL WILL BE FUNDED. 1 CARNEGIE MELLON UNIVERSITY 4400 FIFTH AVE PITTSBURGH PA 15213 501(C)(3) 189610 CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 501(C)(3) 150000 EARLY ROLE OF MICROGLIA IN SYNAPSE LOSS IN ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 501(C)(3) 150000 INVESTIGATING THE MECHANISM OF ENTORHINAL CORTEX HYPERMETABOLISM IN APOE4 TARGETED REPLACEMENT MICE DUKE UNIVERSITY SCHOOL OF MEDICINE 8 DUKE UNIVERSITY MEDICAL CENTER GREENSPACE DURHAM NC 27703 501(C)(3) 151655 PATHWAY CROSS-TALKS ASSOCIATED WITH SEX AND RISK FOR ALZHEIMER'S DISEASE DUKE UNIVERSITY SCHOOL OF MEDICINE 8 DUKE UNIVERSITY MEDICAL CENTER GREENSPACE DURHAM NC 27703 501(C)(3) 112662 THE APOE MIMETIC THERAPEUTIC PEPTIDE CN-105 ATTENUATES AD PATHOLOGY AND IMPROVES FUNCTIONAL OUTCOMES IN A MURINE MODEL OF ALZHEIMER'S DISEASE HARVARD 677 HUNTINGTON AVE BOSTON MA 02115 501(C)(3) 150000 GOLD ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 501(C)(3) 250000 LAN ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAE L LEVY PLACE NEW YORK NY 10029 501(C)(3) 150000 INTERSECTION OF MICROGLIAL TRANSCRIPTOMES TO IDENTIFY KEY ALZHEIMER'S PATHWAYS OF BRAIN PHAGOCYTES JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK NY 10065 501(C)(3) 120006 INTERSECTIMAX REGULATION OF MICROGLIAL LYSOSOME ACIDIFICATION MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 150000 GAU ROLE OF NEUREXINS IN ALZHEIMER'S DISEASE PATHOPHYSIOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 150000 EXTRACELLULAR VESICLE-BASED TARGETING OF CD33-MEDIATED PATHOLOGY FOR ALZHEIMER'S DISEASE THERAPY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 145004 CIRCUITS: IPS CELLS AND THE HUMAN BRAIN MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 021394307 501(C)(3) 93844 ROLE OF THE BLOOD-BRAIN BARRIER IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 021394307 501(C)(3) 250000 STUDYING THE FUNCTIONAL CONSEQUENCES OF ALZHEIMER'S DISEASE RISK VARIANTS IN THE CLU AND ABCA7 GENES USING BOTH HUMAN AND MOUSE MODELS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 021394307 501(C)(3) 400000 CIRCUITS: FUNCTIONAL ANALYSIS OF ALZHEIMER'S DISEASE RISK GENES USING HUMAN-INDUCED PLURIPOTENT STEM CELLS METHODIST HOSPITAL PO BOX 4384 HOUSTON TX 772104384 501(C)(3) 150000 HIGH CONTENT DRUG SCREEN USING A NOVEL 3D CELL MODEL OF ALZHEIMER'S DISEASE MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 400000 MICROGLIAL CORE/CD33 AND ALZHEIMER'S DISEASE: FROM BIOLOGY TO THERAPY MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 200000 ROLE OF BLOOD-BRAIN BARRIER FUNCTION IN ALZHEIMER'S DISEASE PATHOGENESIS INVESTIGATED USING A 3D MICROFLUIDIC PLATFORM MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 400000 3D NEURAL CORE/HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN NEURAL CELL CULTURE SYSTEMS MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 375000 ROT SEARCH FOR FEMALE-SPECIFIC FACTORS CONTRIBUTING TO RISK FOR ALZHEIMER'S DISEASE MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 175000 MOI. EXT AB EXPRESSION PROTECTS THE BRAIN FROM HERPES SIMPLEX VIRUS (EXTENSION) MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 1500000 ALZHEIMER'S GENOME PROJECT MGH GENETICS AND AGING 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 173750 GENES TO THERAPIES MGH RESEARCH FINANCE PO BOX 414876 BOSTON MA 02114 501(C)(3) 200000 SYSTEMIC INFLAMMATORY NETWORKS IN ALZHEIMER'S DISEASE PALO ALTO VETERANS INSTITUTE FOR RESEARCH PO BOX V-38 PALO ALTO CA 94304 501(C)(3) 150000 REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION REGENTS OF THE UNIVERSITY OF CALIFORNIA 300 LAKESIDE DRIVE 6TH FLOOR OAKLAND CA 94612 501(C)(3) 125000 COMBINATION OF ANTI-AB & GROWTH FACTOR THERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA 300 LAKESIDE DRIVE 6TH FLOOR OAKLAND CA 94612 501(C)(3) 125000 IDENTIFICATION OF PROTECTIVE HUMAN IMMUNE RESPONSE FOR ALZHEIMER'S DISEASE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 501(C)(3) 95000 CIRCUITS: WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND ALZHEIMER'S DISEASE HUMAN BRAIN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 10901 N TORREY PINES ROAD LA JOLLA CA 92037 501(C)(3) 150000 SORA ATTENUATES A TOXICITY THROUGH INTERACTIONS WITH EPHA4 STANFORD UNIVERSITY 3172 PORTER DRIVE PALO ALTO CA 943041212 501(C)(3) 150000 UNDERSTANDING REACTIVE ASTROCYTES AND THEIR ROLES IN ALZHEIMER'S DISEASE THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 501(C)(3) 750000 CIRCUITS: PRODUCTION CENTER FOR REFERENCE AND VARIATION GENE-REGULATORY MAPS THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 250000 UNCOVERING DETERMINANTS OF NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 450000 DISCOVERY OF CK1 ACTIVATORS FOR INDUCING THE AUTOPHAGIC DEGRADATION OF APP BETA-CTF THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 022151301 501(C)(3) 150000 ALZHEIMER'S DISEASE DRUG DISCOVERY IN 3D THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 022151301 501(C)(3) 129373 DEVELOPMENT OF NOVEL APP DIMERIZATION INHIBITORS THAT LOWER AB LEVELS THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 144450 ACCELERATION OF FDA REQUIRED GLP GENE TOXICITY STUDIES WITH THE GSM BPN-15606 THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 250000 ALZHEIMER DISEASE-ASSOCIATED MUTATIONS IN PROTEIN KINASE C THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 194950 BINDING SITE CHARACTERIZATION OF A NOVEL PYRIDAZINE-DERIVED CLASS OF Y-SECRETASE MODULATORS UNIVERSITY OF CHICAGO 947 E 58TH STREET CHICAGO IL 60637 501(C)(3) 250000 IN VITRO AND IN VIVO ANALYSIS OF APP S198P AND V675I VARIANTS UNIVERSITY OF CHICAGO 947 E 58TH STREET CHICAGO IL 60637 501(C)(3) 250000 MECHANISMS BY WHICH THE GUT MICROBIOME INFLUENCES AMYLOID DEPOSITION AND NEUROINFLAMMATION IN MOUSE MODELS OF ALZHEIMER'S DISEASE UNIVERSITY OF CHICAGO 947 E 58TH STREET CHICAGO IL 60637 501(C)(3) 150000 BIN1 IN ALZHEIMER'S DISEASE NEUROPATHOLOGY UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 9201 UNIVERSITY CITY BLVD CHARLOTTE NC 282230001 501(C)(3) 150000 3DDS: A 3-D HUMAN NEURAL CELL CULTURE SYSTEM FOR STUDYING NEURON-MICROGLIA INTERACTION IN ALZHEIMER'S DISEASE UNIVERSITY OF ROCHESTER 601 ELMWOOD AVENUE ROCHESTER NY 14642 501(C)(3) 150000 WILL RESTORATION OF NORMAL GLYMPHATIC FUNCTION SLOW PROGRESSION OF COGNITIVE DECLINE AND AMYLOID PLAQUES IN A MURINE ALZHEIMER MODEL? UNIVERSITY OF SOUTHERN CALIFORNIA 3720 FLOWER STREET LOS ANGELES CA 900892821 501(C)(3) 225000 PICALM GENE THERAPY AND DRUG SCREENING FOR ABETA CLEARANCE UNIVERSITY OF SOUTHERN CALIFORNIA 3720 FLOWER STREET LOS ANGELES CA 900892821 501(C)(3) 150000 TARGETING BENEFICIAL INNATE IMMUNITY IN ALZHEIMER'S BY IRAK-M DELETION UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 501(C)(3) 150000 THE ROLE OF MENINGEAL LYMPHATICS IN CLEANSING THE BRAIN: IMPLICATIONS FOR ALZHEIMER'S DISEASE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 501(C)(3) 100000 CELL CYCLE RE-ENTRY IN 3-D HUMAN NEURON CULTURES WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 150000 MODELING NEURONAL AGING IN SPECIFIC SUBTYPES OF HUMAN NEURONS BY MICRORNA-MEDIATED NEURONAL REPROGRAMMING WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 49600 CHARACTERIZATION OF HUMAN APOEFL/FL TARGETED GENE REPLACEMENT MICE WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 250000 THE BIOLOGICAL IMPACT OF TREM LOCUS MUTATIONS IN ALZHEIMER'S DISEASE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 501(C)(3) 150000 MODELING DNA METHYLATION CHANGES IN ALZHEIMER'S DISEASE USING HUMAN-INDUCED PLURIPOTENT STEM CELLS WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 501(C)(3) 155000 CIRCUITS: WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND ALZHEIMER'S DISEASE HUMAN BRAIN YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 501(C)(3) 75000 IMPACT OF INFLAMMASOME DEACTIVATION ON ALZHEIMER'S DISEASE PART I, LINE 2: THE CHAIR OF THE RESEARCH CONSORTIUM (RC) AND SUITABLE MEMBERS OF THE RC AND SCIENTIFIC ADVISORY BOARD (SAB) REVIEW EACH PROPOSAL FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S. THE BOARD OF DIRECTORS OF CURE ALZHEIMER'S FUND PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY MEMBER OF THE RC, SAB OR EXECUTIVE COMMITTEE WILL BE RETURNED TO THE RESEARCHER FOR CLARIFICATION. SUCH QUESTIONS OR CONCERNS MAY RESULT IN MODIFICATION AND RESUBMISSION, OR, IN EXTREME CASES, REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTION, OR REJECTION. THERE IS NO "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION WHEN RESEARCHERS ARE NOTIFIED THAT A PROPOSAL WILL BE FUNDED. X X 0 0 0 0 0 0 0 0 0 TIMOTHY W ARMOUR PRESIDENT & CEO 216933 0 0 0 0 0 0 0 0 0 216933 0 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 161462 0 0 0 0 0 0 0 0 0 161462 0 0 0 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 164984 0 0 0 0 0 0 0 8200 0 173184 0 0 0 BARBARA CHAMBERS SENIOR ENGMT OFFICER, MARKETING & CO 161462 0 0 0 0 0 0 0 8600 0 170062 0 0 0 PART I, LINE 3 A COMPENSATION COMMITTEE REVIEWS ALL COMPENSATION ANNUALLY. X 70 3902516 CLOSE OF BUSINESS 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR AS SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT REVIEWS THE FORM 990 AND PROVIDES COPIES TO THE DIRECTORS BEFORE APPROVING THE FORM FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE PRESIDENT REGULARLY AND CONSISTENTLY MONITORS COMPLIANCE WITH CONFLICTS OF INTEREST BY REQUESTING THAT ALL OFFICERS, DIRECTORS, AND FOUNDERS RADIFY AN ANNUAL STATEMENT DISCLOSING ALL INTERESTS THAT MIGHT CONFLICT WITH ANY INTEREST OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.